Propella Therapeutics, Inc. announced nonclinical data for its lead product candidate, PRL-02, will be presented at the 2022 ASCO Genitourinary (GU) Cancers Symposium. PRL-02 is being evaluated in an ongoing Phase 1 study for patients with advanced prostate cancer; the recommended phase 2 dose will be selected in Q1 2022 based upon pharmacokinetic, safety, clinical pharmacology, and efficacy results.
https://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svg00georgehttps://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svggeorge2022-01-04 09:43:112022-01-04 09:55:25Press Release: Propella Therapeutics Invited to Present at 2022 ASCO Genitourinary (GU) Cancers Symposium and to Participate in the LifeSci Partners 11th Annual Corporate Access Event
Propella Therapeutics, Inc. will be participating in the American Society of Clinical Oncology Genitourinary Cancers Symposium from February 17-19, 2022.
https://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svg00georgehttps://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svggeorge2021-12-08 17:18:312022-01-19 19:52:54Presentation: American Society of Clinical Oncology Genitourinary Cancers Symposium (February 17-19, 2022)
Propella Therapeutics, Inc., a private, clinical-stage biopharmaceutical company developing best-in-class oncology therapeutics, announced the dosing of the first patient in the Phase 1/2a clinical trial studying its lead patented product candidate, PRL-02 (abiraterone decanoate), for the treatment of metastatic prostate cancer.
https://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svg00georgehttps://propellatx.com/wp-content/uploads/2020/04/Propella-logo-horz.svggeorge2021-06-29 15:42:032022-01-04 09:10:09Press Release: Propella Announces First Patient Dosed in Phase 1/2a Trial of PRL-02 for Treatment of Metastatic Prostate Cancer; Next-Generation Androgen Biosynthesis Inhibitor with Long Duration of Activity and Superior Therapeutic Index
Press Release: Propella Therapeutics Invited to Present at 2022 ASCO Genitourinary (GU) Cancers Symposium and to Participate in the LifeSci Partners 11th Annual Corporate Access Event
/in press releases /by georgePropella Therapeutics, Inc. announced nonclinical data for its lead product candidate, PRL-02, will be presented at the 2022 ASCO Genitourinary (GU) Cancers Symposium. PRL-02 is being evaluated in an ongoing Phase 1 study for patients with advanced prostate cancer; the recommended phase 2 dose will be selected in Q1 2022 based upon pharmacokinetic, safety, clinical pharmacology, and efficacy results.
Presentation: American Society of Clinical Oncology Genitourinary Cancers Symposium (February 17-19, 2022)
/in presentations /by georgePropella Therapeutics, Inc. will be participating in the American Society of Clinical Oncology Genitourinary Cancers Symposium from February 17-19, 2022.
Presentation: 40th Annual J.P. Morgan Healthcare Conference (January 10–13, 2022)
/in presentations /by georgePropella Therapeutics, Inc. participated in the 40th Annual J.P. Morgan Healthcare Conference from January 10–13, 2022.
Presentation: 11th Annual LifeSci Partners Corporate Access Event (January 5-7, 2022)
/in presentations /by georgePropella Therapeutics, Inc. participated in the 11th Annual LifeSci Partners Corporate Access Event from January 5-7, 2022.
Presentation: MedInvest Oncology Conference (December 7-10, 2021)
/in presentations /by georgePropella Therapeutics, Inc. presented at the MedInvest Oncology Conference on December 7, 2021.
Press Release: Propella Announces First Patient Dosed in Phase 1/2a Trial of PRL-02 for Treatment of Metastatic Prostate Cancer; Next-Generation Androgen Biosynthesis Inhibitor with Long Duration of Activity and Superior Therapeutic Index
/in press releases /by georgePropella Therapeutics, Inc., a private, clinical-stage biopharmaceutical company developing best-in-class oncology therapeutics, announced the dosing of the first patient in the Phase 1/2a clinical trial studying its lead patented product candidate, PRL-02 (abiraterone decanoate), for the treatment of metastatic prostate cancer.